GM1 Gangliosidosis- Pipeline Insight, 2020
This report can be delivered to the clients within 48-72 Hours
GM1 Gangliosidosis Overview
'GM1 Gangliosidosis Pipeline Insight, 2020' Report By DelveInsight Outlays Comprehensive Insights Of Present Clinical Development Scenario And Growth Prospects Across The GM1 Gangliosidosis Market. A Detailed Picture Of The GM1 Gangliosidosis Pipeline Landscape Is Provided, Which Includes The Disease Overview And GM1 Gangliosidosis Treatment Guidelines.
The Assessment Part Of The Report Embraces In-Depth GM1 Gangliosidosis Commercial Assessment And Clinical Assessment Of The GM1 Gangliosidosis Pipeline Products From The Pre-Clinical Developmental Phase To The Marketed Phase.
In The Report, A Detailed Description Of The Drug Is Proffered Including Mechanism Of Action Of The Drug, Clinical Studies, NDA Approvals (If Any), And Product Development Activities Comprising The Technology, GM1 Gangliosidosis Collaborations, Licensing, Mergers And Acquisition, Funding, Designations, And Other Product-Related Details.
GM1 Gangliosidosis Of Pipeline Development Activities
The Report Provides Insights Into:
SCOPE OF THE REPORT
GM1 Gangliosidosis Overview
'GM1 Gangliosidosis Pipeline Insight, 2020' Report By DelveInsight Outlays Comprehensive Insights Of Present Clinical Development Scenario And Growth Prospects Across The GM1 Gangliosidosis Market. A Detailed Picture Of The GM1 Gangliosidosis Pipeline Landscape Is Provided, Which Includes The Disease Overview And GM1 Gangliosidosis Treatment Guidelines.
The Assessment Part Of The Report Embraces In-Depth GM1 Gangliosidosis Commercial Assessment And Clinical Assessment Of The GM1 Gangliosidosis Pipeline Products From The Pre-Clinical Developmental Phase To The Marketed Phase.
In The Report, A Detailed Description Of The Drug Is Proffered Including Mechanism Of Action Of The Drug, Clinical Studies, NDA Approvals (If Any), And Product Development Activities Comprising The Technology, GM1 Gangliosidosis Collaborations, Licensing, Mergers And Acquisition, Funding, Designations, And Other Product-Related Details.
GM1 Gangliosidosis Of Pipeline Development Activities
The Report Provides Insights Into:
- All Of The Companies That Are Developing Therapies For The Treatment Of GM1 Gangliosidosis With Aggregate Therapies Developed By Each Company For The Same.
- Different Therapeutic Candidates Segmented Into Early-Stage, Mid-Stage And Late Stage Of Development For The GM1 Gangliosidosis Treatment.
- GM1 Gangliosidosis Key Players Involved In Targeted Therapeutics Development With Respective Active And Inactive (Dormant Or Discontinued) Projects.
- Drugs Under Development Based On The Stage Of Development, Route Of Administration, Target Receptor, Monotherapy Or Combination Therapy, A Different Mechanism Of Action, And Molecular Type.
- Detailed Analysis Of Collaborations (Company-Company Collaborations And Company-Academia Collaborations), Licensing Agreement And Financing Details For Future Advancement Of GM1 Gangliosidosis Market.
- The Report Is Built Using Data And Information Traced From The Researcher's Proprietary Databases, Company/University Websites, Clinical Trial Registries, Conferences, SEC Filings, Investor Presentations, And Featured Press Releases From Company/University Web Sites And Industry-Specific Third-Party Sources, Etc.
- In-Depth GM1 Gangliosidosis Commercial Assessment Of Products
- GM1 Gangliosidosis Clinical Assessment Of Products
SCOPE OF THE REPORT
- The GM1 Gangliosidosis Report Provides An Overview Of Therapeutic Pipeline Activity And Therapeutic Assessment Of The Products By Development Stage, Product Type, Route Of Administration, Molecule Type, And MOA Type For GM1 Gangliosidosis Across The Complete Product Development Cycle, Including All Clinical And Nonclinical Stages.
- It Comprises Of Detailed Profiles Of GM1 Gangliosidosis Therapeutic Products With Key Coverage Of Developmental Activities, Including Technology, Collaborations, Licensing, Mergers And Acquisition, Funding, Designations And Other Product-Related Details
- Detailed GM1 Gangliosidosis Research And Development Progress And Trial Details, Results Wherever Available, Are Also Included In The Pipeline Study.
- Coverage Of Dormant And Discontinued Pipeline Projects Along With The Reasons If Available Across GM1 Gangliosidosis.
- A Better Understanding of Disease Pathogenesis Contributing To The Development Of Novel Therapeutics For GM1 Gangliosidosis.
- In The Coming Years, The GM1 Gangliosidosis Market Is Set To Change Due To The Rising Awareness Of The Disease, And Incremental Healthcare Spending Across The World; Which Would Expand The Size Of The Market To Enable The Drug Manufacturers To Penetrate More Into The Market.
- The Companies And Academics That Are Working To Assess Challenges And Seek Opportunities That Could Influence GM1 Gangliosidosis R&D. The Therapies Under Development Are Focused On Novel Approaches To Treat/Improve The Disease Condition.
- A Detailed Portfolio of Major Pharma Players Who Are Involved In Fueling The GM1 Gangliosidosis Treatment Market. Several Potential Therapies For GM1 Gangliosidosis Are Under Investigation. With The Expected Launch Of These Emerging Therapies, It Is Expected That There Will Be A Significant Impact On The GM1 Gangliosidosis Market Size In The Coming Years.
- Our In-Depth Analysis Of The Pipeline Assets (In Early-Stage, Mid-Stage And Late Stage Of Development For The Treatment Of GM1 Gangliosidosis ) Includes Therapeutic Assessment And Comparative Analysis. This Will Support The Clients In The Decision-Making Process Regarding Their Therapeutic Portfolio By Identifying The Overall Scenario Of The Research And Development Activities.
- What Are The Current Options For GM1 Gangliosidosis Treatment?
- How Many Companies Are Developing Therapies For The Treatment Of GM1 Gangliosidosis?
- What Are The Principal Therapies Developed By These Companies In The Industry?
- How Many Therapies Are Developed By Each Company For The Treatment Of GM1 Gangliosidosis?
- How Many GM1 Gangliosidosis Emerging Therapies Are In Early-Stage, Mid-Stage, And Late Stage Of Development For The Treatment Of GM1 Gangliosidosis?
- Out Of Total Pipeline Products, How Many Therapies Are Given As A Monotherapy And In Combination With Other Therapies?
- What Are The Key Collaborations (Industry-Industry, Industry-Academia), Mergers And Acquisitions, And Major Licensing Activities That Will Impact GM1 Gangliosidosis Market?
- Which Are The Dormant And Discontinued Products And The Reasons For The Same?
- What Is The Unmet Need For Current Therapies For The Treatment Of GM1 Gangliosidosis?
- What Are The Recent Novel Therapies, Targets, Mechanisms Of Action And Technologies Developed To Overcome The Limitation Of Existing GM1 Gangliosidosis Therapies?
- What Are The Clinical Studies Going On For GM1 Gangliosidosis And Their Status?
- What Are The Results Of The Clinical Studies And Their Safety And Efficacy?
- What Are The Key Designations That Have Been Granted For The Emerging Therapies For GM1 Gangliosidosis?
- How Many Patents Are Granted And Pending For The Emerging Therapies For The Treatment Of GM1 Gangliosidosis?
1. REPORT INTRODUCTION
2. GM1 GANGLIOSIDOSIS
2.1. Overview
2.2. History
2.3. GM1 Gangliosidosis Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. GM1 Gangliosidosis Diagnosis
2.6.1. Diagnostic Guidelines
3. GM1 GANGLIOSIDOSIS CURRENT TREATMENT PATTERNS
3.1. GM1 Gangliosidosis Treatment Guidelines
4. GM1 GANGLIOSIDOSIS - DELVEINSIGHT'S ANALYTICAL PERSPECTIVE
4.1. In-depth Commercial Assessment
4.1.1. GM1 Gangliosidosis companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. GM1 Gangliosidosis Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. GM1 Gangliosidosis Acquisition Analysis
5. THERAPEUTIC ASSESSMENT
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. GM1 GANGLIOSIDOSIS LATE STAGE PRODUCTS (PHASE-III)
7. GM1 GANGLIOSIDOSIS MID STAGE PRODUCTS (PHASE-II)
8. EARLY STAGE PRODUCTS (PHASE-I)
9. PRE-CLINICAL PRODUCTS AND DISCOVERY STAGE PRODUCTS
10. INACTIVE PRODUCTS
11. DORMANT PRODUCTS
12. GM1 GANGLIOSIDOSIS DISCONTINUED PRODUCTS
13. GM1 GANGLIOSIDOSIS PRODUCT PROFILES
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
Detailed information in the report?
14. GM1 GANGLIOSIDOSIS KEY COMPANIES
15. GM1 GANGLIOSIDOSIS KEY PRODUCTS
16. DORMANT AND DISCONTINUED PRODUCTS
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. GM1 GANGLIOSIDOSIS UNMET NEEDS
18. GM1 GANGLIOSIDOSIS FUTURE PERSPECTIVES
19. GM1 GANGLIOSIDOSIS ANALYST REVIEW
20. APPENDIX
21. REPORT METHODOLOGY
21.1. Secondary Research
21.2. Expert Panel Validation
2. GM1 GANGLIOSIDOSIS
2.1. Overview
2.2. History
2.3. GM1 Gangliosidosis Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. GM1 Gangliosidosis Diagnosis
2.6.1. Diagnostic Guidelines
3. GM1 GANGLIOSIDOSIS CURRENT TREATMENT PATTERNS
3.1. GM1 Gangliosidosis Treatment Guidelines
4. GM1 GANGLIOSIDOSIS - DELVEINSIGHT'S ANALYTICAL PERSPECTIVE
4.1. In-depth Commercial Assessment
4.1.1. GM1 Gangliosidosis companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. GM1 Gangliosidosis Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. GM1 Gangliosidosis Acquisition Analysis
5. THERAPEUTIC ASSESSMENT
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. GM1 GANGLIOSIDOSIS LATE STAGE PRODUCTS (PHASE-III)
7. GM1 GANGLIOSIDOSIS MID STAGE PRODUCTS (PHASE-II)
8. EARLY STAGE PRODUCTS (PHASE-I)
9. PRE-CLINICAL PRODUCTS AND DISCOVERY STAGE PRODUCTS
10. INACTIVE PRODUCTS
11. DORMANT PRODUCTS
12. GM1 GANGLIOSIDOSIS DISCONTINUED PRODUCTS
13. GM1 GANGLIOSIDOSIS PRODUCT PROFILES
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
Detailed information in the report?
14. GM1 GANGLIOSIDOSIS KEY COMPANIES
15. GM1 GANGLIOSIDOSIS KEY PRODUCTS
16. DORMANT AND DISCONTINUED PRODUCTS
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. GM1 GANGLIOSIDOSIS UNMET NEEDS
18. GM1 GANGLIOSIDOSIS FUTURE PERSPECTIVES
19. GM1 GANGLIOSIDOSIS ANALYST REVIEW
20. APPENDIX
21. REPORT METHODOLOGY
21.1. Secondary Research
21.2. Expert Panel Validation
LIST OF TABLES
Table 1: GM1 Gangliosidosis Diagnostic Guidelines
Table 2: GM1 Gangliosidosis Treatment Guidelines
Table 3: Assessment Summary
Table 4: Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5: GM1 Gangliosidosis Acquisition Analysis
Table 6: Assessment by Phase of Development
Table 7: Assessment by Product Type (Mono / Combination)
Table 8: Assessment by Stage and Product Type
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Assessment by MOA
Table 14: Assessment by Stage and MOA
Table 15: Assessment by Target
Table 16: Assessment by Stage and Target
Table 17: GM1 Gangliosidosis Late Stage Products (Phase-III)
Table 18: GM1 Gangliosidosis Mid Stage Products (Phase-II)
Table 19: GM1 Gangliosidosis Early Stage Products (Phase-I)
Table 20: Pre-clinical and Discovery Stage Products
Table 21: Inactive Products
Table 22: Dormant Products
Table 23: Discontinued Products
Table 1: GM1 Gangliosidosis Diagnostic Guidelines
Table 2: GM1 Gangliosidosis Treatment Guidelines
Table 3: Assessment Summary
Table 4: Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5: GM1 Gangliosidosis Acquisition Analysis
Table 6: Assessment by Phase of Development
Table 7: Assessment by Product Type (Mono / Combination)
Table 8: Assessment by Stage and Product Type
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Assessment by MOA
Table 14: Assessment by Stage and MOA
Table 15: Assessment by Target
Table 16: Assessment by Stage and Target
Table 17: GM1 Gangliosidosis Late Stage Products (Phase-III)
Table 18: GM1 Gangliosidosis Mid Stage Products (Phase-II)
Table 19: GM1 Gangliosidosis Early Stage Products (Phase-I)
Table 20: Pre-clinical and Discovery Stage Products
Table 21: Inactive Products
Table 22: Dormant Products
Table 23: Discontinued Products
LIST OF FIGURES
Figure 1: Disease Overview
Figure 2: History
Figure 3: Symptoms
Figure 4: Causes
Figure 5: Pathophysiology
Figure 6: Diagnostic Guidelines
Figure 7: Treatment Guidelines
Figure 8: GM1 Gangliosidosis companies collaborations, Licensing, Acquisition -Deal Value Trends
Figure 9: Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10: GM1 Gangliosidosis Acquisition Analysis
Figure 11: Assessment by Phase of Development
Figure 12: Assessment by Product Type (Mono / Combination)
Figure 13: Assessment by Stage and Product Type
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Assessment by MOA
Figure 19: Assessment by Stage and MOA
Figure 20: Late Stage Products (Phase-III)
Figure 21: Mid Stage Products (Phase-II)
Figure 22: Early Stage Products (Phase-I)
Figure 23: Pre-clinical and Discovery Stage Products
Figure 24: Inactive Products
Figure 25: Dormant Products
Figure 26: Discontinued Products
Figure 27: Unmet Needs
Figure 1: Disease Overview
Figure 2: History
Figure 3: Symptoms
Figure 4: Causes
Figure 5: Pathophysiology
Figure 6: Diagnostic Guidelines
Figure 7: Treatment Guidelines
Figure 8: GM1 Gangliosidosis companies collaborations, Licensing, Acquisition -Deal Value Trends
Figure 9: Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10: GM1 Gangliosidosis Acquisition Analysis
Figure 11: Assessment by Phase of Development
Figure 12: Assessment by Product Type (Mono / Combination)
Figure 13: Assessment by Stage and Product Type
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Assessment by MOA
Figure 19: Assessment by Stage and MOA
Figure 20: Late Stage Products (Phase-III)
Figure 21: Mid Stage Products (Phase-II)
Figure 22: Early Stage Products (Phase-I)
Figure 23: Pre-clinical and Discovery Stage Products
Figure 24: Inactive Products
Figure 25: Dormant Products
Figure 26: Discontinued Products
Figure 27: Unmet Needs
